Abstract
Objective High-risk human papilloma virus (HR-HPV) is found to be responsible for 4.5% of all cancer, mainly, cervical cancer. The prevalence of HR-HPV and its significant association with cervical lesions are not well-known in Saudi Arabia. We aim here, to disclose the distribution of HR-HPV genotypes and correlate its association with cervical lesions which could help in customizing regional-specific vaccine-combinations and screening programs.
Methods Over 6 years (2013 - 2018), 5091 Papanicolaou (Pap) smears results along with HR-HPV test results (whenever done), were collected from the King Fahd University Hospital (KFHU) Information System, in addition to the patients’ age and nationality. Statistical analysis was performed using SPSS IBM.
Results Out of 5091 Pap smears, only 1.89% (n=96) were abnormal; 0.18% (n=9) were malignant (7 SCC and 2 adenocarcinomas) and 1.7% (n=87) showed pre-cancerous lesions (44 ASCUS, 17 LSIL, 12 HSIL, and 14 AGC/AGUS). Out of 170 patients co-tested for HR-HPV, only 13.5% (n=23) had positive results (5 cases were positive for HR-HPV16, 1 case was positive for both HR-HPV16&18 and the remaining 17 cases were positive for HR-HPV other than 16/18). HR-HPV findings showed a significant correlation with the Pap smear results (P-value 0.000), however, it didn’t show any significant correlation with the patients’ age and/or nationality.
Discussion Our study showed a unique distribution of HR-HPV genotypes, distinguished from the international distribution, which reflects a different geographical representation of infection patterns. Furthermore, the high association of normal Pap smears with HR-HPV highlights the need, along with Pap smear, for HR-HPV genotype tests for all women at risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded By DSR at Imam Abdulrahman Bin Faisal University (Project number 201815).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon a reasonable request
